Vitrolife private equity investment committee paper - business plan

Bibliographic Details
Main Author: Berg, Laura
Publication Date: 2023
Format: Master thesis
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/176338
Summary: The target company, Vitrolife provides Medical Consumables, Technological Devices (C&T) and Genetic Testing services (GT) for in-vitro fertilization. C&T has a market size of SEK 15bn (CAGR of 14.3%) while GT’s market size is SEK 41bn (CAGR of 6.7%). Value creation is driven through an AI software partnership, the Eastern Europe Penetration and the acquisition of Virtus Health. Most of the value is driven by inorganic growth (50%). Based on a 16.7x exit multiple and an Enterprise Value of SEK 17,250m, a MM of 3.6x can be realized over the holding period. Sources of funds include SEK 5,693m (5.5x) debt and SEK 12,418m (12x) equity.
id RCAP_a5a4e860d2ed1516b1edd333993fbb6c
oai_identifier_str oai:run.unl.pt:10362/176338
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Vitrolife private equity investment committee paper - business planPrivate equityAcquisitionVitrolifeLeveraged buyoutDomínio/Área Científica::Ciências Sociais::Economia e GestãoThe target company, Vitrolife provides Medical Consumables, Technological Devices (C&T) and Genetic Testing services (GT) for in-vitro fertilization. C&T has a market size of SEK 15bn (CAGR of 14.3%) while GT’s market size is SEK 41bn (CAGR of 6.7%). Value creation is driven through an AI software partnership, the Eastern Europe Penetration and the acquisition of Virtus Health. Most of the value is driven by inorganic growth (50%). Based on a 16.7x exit multiple and an Enterprise Value of SEK 17,250m, a MM of 3.6x can be realized over the holding period. Sources of funds include SEK 5,693m (5.5x) debt and SEK 12,418m (12x) equity.Santos, Fábio SoaresRUNBerg, Laura2024-12-10T14:59:52Z2024-01-102023-12-202024-01-10T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10362/176338TID:203681460enginfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-12-16T01:32:29Zoai:run.unl.pt:10362/176338Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T19:19:11.488663Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Vitrolife private equity investment committee paper - business plan
title Vitrolife private equity investment committee paper - business plan
spellingShingle Vitrolife private equity investment committee paper - business plan
Berg, Laura
Private equity
Acquisition
Vitrolife
Leveraged buyout
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
title_short Vitrolife private equity investment committee paper - business plan
title_full Vitrolife private equity investment committee paper - business plan
title_fullStr Vitrolife private equity investment committee paper - business plan
title_full_unstemmed Vitrolife private equity investment committee paper - business plan
title_sort Vitrolife private equity investment committee paper - business plan
author Berg, Laura
author_facet Berg, Laura
author_role author
dc.contributor.none.fl_str_mv Santos, Fábio Soares
RUN
dc.contributor.author.fl_str_mv Berg, Laura
dc.subject.por.fl_str_mv Private equity
Acquisition
Vitrolife
Leveraged buyout
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
topic Private equity
Acquisition
Vitrolife
Leveraged buyout
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
description The target company, Vitrolife provides Medical Consumables, Technological Devices (C&T) and Genetic Testing services (GT) for in-vitro fertilization. C&T has a market size of SEK 15bn (CAGR of 14.3%) while GT’s market size is SEK 41bn (CAGR of 6.7%). Value creation is driven through an AI software partnership, the Eastern Europe Penetration and the acquisition of Virtus Health. Most of the value is driven by inorganic growth (50%). Based on a 16.7x exit multiple and an Enterprise Value of SEK 17,250m, a MM of 3.6x can be realized over the holding period. Sources of funds include SEK 5,693m (5.5x) debt and SEK 12,418m (12x) equity.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-20
2024-12-10T14:59:52Z
2024-01-10
2024-01-10T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/176338
TID:203681460
url http://hdl.handle.net/10362/176338
identifier_str_mv TID:203681460
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598013983948800

Similar Items